{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:48:29Z","timestamp":1787532509341,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chronic lymphocytic leukemia (CLL) is a heterogeneous B cell malignancy characterized by the accumulation of functionally incompetent B lymphocytes. Despite the availability of highly effective treatments, CLL remains incurable, and the factors contributing to disease progression are not fully understood. Autoimmune complications frequently arise in CLL patients and are associated with poor clinical prognosis. This study investigates the connection between plasma cell-mediated autoimmunity and CLL progression using a mouse model that expresses an active Receptor Activator of NF-\u03baB (RANK) in B cells (RK mice), where autoimmune manifestations coexist with CLL. Transcriptional profiling of RANK-driven leukemic cells revealed a more indolent form of CLL compared to the classical TCL1 model. The discovery of near-identical CDR3 regions in both plasma and CLL cells of RK mice suggests a shared progenitor and antigen driving both conditions. Deletion of Blimp-1, which prevents plasma cell differentiation, initially enhanced B1\/CLL formation in young mice but nearly halted CLL progression, highlighting the significant influence of autoimmune complications on disease outcomes. This research underscores the intertwined nature of autoimmunity and CLL, suggesting that targeting inflammatory pathways could offer therapeutic potential for managing both conditions.<\/jats:p>","DOI":"10.1038\/s41598-025-86876-1","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:57:04Z","timestamp":1738601824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoimmunity promotes chronic lymphocytic leukemia progression in an indolent disease model"],"prefix":"10.1038","volume":"15","author":[{"given":"Lisa","family":"Pfeuffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Trozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Ruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"86876_CR1","doi-asserted-by":"publisher","unstructured":"Shaffer, A. L. 3, Young, R. M., Staudt, L. M. & rd, & Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30, 565\u2013610. https:\/\/doi.org\/10.1146\/annurev-immunol-020711-075027 (2012).","DOI":"10.1146\/annurev-immunol-020711-075027"},{"key":"86876_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/17474086.2016.1180972","volume":"9","author":"JL Koff","year":"2016","unstructured":"Koff, J. L. & Flowers, C. R. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev. Hematol. 9, 553\u2013561. https:\/\/doi.org\/10.1080\/17474086.2016.1180972 (2016).","journal-title":"Expert Rev. Hematol."},{"key":"86876_CR3","doi-asserted-by":"publisher","unstructured":"Singh, M. et al. Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. Cell 180, 878\u2013894 e819 (2020). https:\/\/doi.org\/10.1016\/j.cell.2020.01.029","DOI":"10.1016\/j.cell.2020.01.029"},{"key":"86876_CR4","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724\u20133734. https:\/\/doi.org\/10.1182\/blood-2010-05-282632 (2010).","journal-title":"Blood"},{"key":"86876_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107, 265\u2013276. https:\/\/doi.org\/10.1182\/blood-2005-06-2508 (2006).","journal-title":"Blood"},{"key":"86876_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","volume":"2014","author":"JR Cerhan","year":"2014","unstructured":"Cerhan, J. R. et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-hodgkin Lymphoma Subtypes Project. J. Natl. Cancer Inst. Monogr. 2014, 15\u201325. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu010 (2014).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"86876_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848\u20131854 (1999).","journal-title":"Blood"},{"key":"86876_CR8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840\u20131847 (1999).","journal-title":"Blood"},{"key":"86876_CR9","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1172\/JCI24387","volume":"115","author":"M Herve","year":"2005","unstructured":"Herve, M. et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. 115, 1636\u20131643. https:\/\/doi.org\/10.1172\/JCI24387 (2005).","journal-title":"J. Clin. Invest."},{"key":"86876_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.20040544","volume":"200","author":"BT Messmer","year":"2004","unstructured":"Messmer, B. T. et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 200, 519\u2013525. https:\/\/doi.org\/10.1084\/jem.20040544 (2004).","journal-title":"J. Exp. Med."},{"key":"86876_CR11","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi, D. et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin. Cancer Res. 15, 4415\u20134422. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3266 (2009).","journal-title":"Clin. Cancer Res."},{"key":"86876_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2020007039","volume":"137","author":"A Agathangelidis","year":"2021","unstructured":"Agathangelidis, A. et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood 137, 1365\u20131376. https:\/\/doi.org\/10.1182\/blood.2020007039 (2021).","journal-title":"Blood"},{"key":"86876_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa040857","volume":"351","author":"LZ Rassenti","year":"2004","unstructured":"Rassenti, L. Z. et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl. J. Med. 351, 893\u2013901. https:\/\/doi.org\/10.1056\/NEJMoa040857 (2004).","journal-title":"N Engl. J. Med."},{"key":"86876_CR14","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M Crespo","year":"2003","unstructured":"Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl. J. Med. 348, 1764\u20131775. https:\/\/doi.org\/10.1056\/NEJMoa023143 (2003).","journal-title":"N Engl. J. Med."},{"key":"86876_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminoncol.2006.01.011","volume":"33","author":"TJ Hamblin","year":"2006","unstructured":"Hamblin, T. J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 33, 230\u2013239. https:\/\/doi.org\/10.1053\/j.seminoncol.2006.01.011 (2006).","journal-title":"Semin Oncol."},{"key":"86876_CR16","doi-asserted-by":"publisher","unstructured":"Dearden, C. Disease-specific complications of chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 450\u2013456. https:\/\/doi.org\/10.1182\/asheducation-2008.1.450 (2008).","DOI":"10.1182\/asheducation-2008.1.450"},{"key":"86876_CR17","doi-asserted-by":"publisher","unstructured":"Fattizzo, B. & Barcellini, W. Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects. Front. Oncol. 9, 1435. https:\/\/doi.org\/10.3389\/fonc.2019.01435 (2019).","DOI":"10.3389\/fonc.2019.01435"},{"key":"86876_CR18","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","volume":"116","author":"C Moreno","year":"2010","unstructured":"Moreno, C. et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 116, 4771\u20134776. https:\/\/doi.org\/10.1182\/blood-2010-05-286500 (2010).","journal-title":"Blood"},{"key":"86876_CR19","first-page":"828","volume":"8","author":"A Duek","year":"2006","unstructured":"Duek, A., Shvidel, L., Braester, A. & Berrebi, A. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr. Med. Assoc. J. 8, 828\u2013831 (2006).","journal-title":"Isr. Med. Assoc. J."},{"key":"86876_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3324\/haematol.2010.022079","volume":"95","author":"C Visco","year":"2010","unstructured":"Visco, C. et al. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica 95, 1230\u20131232. https:\/\/doi.org\/10.3324\/haematol.2010.022079 (2010).","journal-title":"Haematologica"},{"key":"86876_CR21","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398 (2018).","journal-title":"Blood"},{"key":"86876_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/leu.2010.278","volume":"25","author":"J Rossignol","year":"2011","unstructured":"Rossignol, J. et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 25, 473\u2013478. https:\/\/doi.org\/10.1038\/leu.2010.278 (2011).","journal-title":"Leukemia"},{"key":"86876_CR23","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman, S. E. et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 123, 3286\u20133295. https:\/\/doi.org\/10.1182\/blood-2014-02-548610 (2014).","journal-title":"Blood"},{"key":"86876_CR24","doi-asserted-by":"publisher","first-page":"E183","DOI":"10.1002\/ajh.25480","volume":"94","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel, A. et al. Ibrutinib and Idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. Am. J. Hematol. 94, E183\u2013E185. https:\/\/doi.org\/10.1002\/ajh.25480 (2019).","journal-title":"Am. J. Hematol."},{"key":"86876_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst, B. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019 (2021).","journal-title":"Ann. Oncol."},{"key":"86876_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717\u2013721. https:\/\/doi.org\/10.1038\/nature07968 (2009).","journal-title":"Nature"},{"key":"86876_CR27","doi-asserted-by":"publisher","unstructured":"Alankus, B. et al. Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. J. Exp. Med. 218 https:\/\/doi.org\/10.1084\/jem.20200517 (2021).","DOI":"10.1084\/jem.20200517"},{"key":"86876_CR28","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi, R. et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. U S A. 99, 6955\u20136960. https:\/\/doi.org\/10.1073\/pnas.102181599 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"86876_CR29","doi-asserted-by":"publisher","unstructured":"Yan, X. J. et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U S A. 103, 11713\u201311718. https:\/\/doi.org\/10.1073\/pnas.0604564103 (2006).","DOI":"10.1073\/pnas.0604564103"},{"key":"86876_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.humimm.2012.11.019","volume":"74","author":"Z Zhou","year":"2013","unstructured":"Zhou, Z. et al. Blimp-1 siRNA inhibits B cell differentiation and prevents the development of lupus in mice. Hum. Immunol. 74, 297\u2013301. https:\/\/doi.org\/10.1016\/j.humimm.2012.11.019 (2013).","journal-title":"Hum. Immunol."},{"key":"86876_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s1074-7613(03)00267-x","volume":"19","author":"M Shapiro-Shelef","year":"2003","unstructured":"Shapiro-Shelef, M. et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19, 607\u2013620. https:\/\/doi.org\/10.1016\/s1074-7613(03)00267-x (2003).","journal-title":"Immunity"},{"key":"86876_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1084\/jem.20040973","volume":"200","author":"A Kallies","year":"2004","unstructured":"Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J. Exp. Med. 200, 967\u2013977. https:\/\/doi.org\/10.1084\/jem.20040973 (2004).","journal-title":"J. Exp. Med."},{"key":"86876_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.celrep.2018.06.035","volume":"24","author":"CS Setz","year":"2018","unstructured":"Setz, C. S. et al. PI3K-Mediated Blimp-1 activation controls B Cell Selection and Homeostasis. Cell. Rep. 24, 391\u2013405. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.035 (2018).","journal-title":"Cell. Rep."},{"key":"86876_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41408-024-01123-6","volume":"14","author":"L Pfeuffer","year":"2024","unstructured":"Pfeuffer, L. et al. B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation. Blood Cancer J. 14, 151. https:\/\/doi.org\/10.1038\/s41408-024-01123-6 (2024).","journal-title":"Blood Cancer J."},{"key":"86876_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","volume":"18","author":"J Mandelbaum","year":"2010","unstructured":"Mandelbaum, J. et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 18, 568\u2013579. https:\/\/doi.org\/10.1016\/j.ccr.2010.10.030 (2010).","journal-title":"Cancer Cell."},{"key":"86876_CR36","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","volume":"119","author":"A Agathangelidis","year":"2012","unstructured":"Agathangelidis, A. et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119, 4467\u20134475. https:\/\/doi.org\/10.1182\/blood-2011-11-393694 (2012).","journal-title":"Blood"},{"key":"86876_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","volume":"109","author":"K Stamatopoulos","year":"2007","unstructured":"Stamatopoulos, K. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109, 259\u2013270. https:\/\/doi.org\/10.1182\/blood-2006-03-012948 (2007).","journal-title":"Blood"},{"key":"86876_CR38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","volume":"33","author":"N Zaborsky","year":"2019","unstructured":"Zaborsky, N. et al. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia 33, 957\u2013968. https:\/\/doi.org\/10.1038\/s41375-018-0260-4 (2019).","journal-title":"Leukemia"},{"key":"86876_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13578-022-00795-6","volume":"12","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. Single-cell genomics identifies distinct B1 cell developmental pathways and reveals aging-related changes in the B-cell receptor repertoire. Cell. Biosci. 12, 57. https:\/\/doi.org\/10.1186\/s13578-022-00795-6 (2022).","journal-title":"Cell. Biosci."},{"key":"86876_CR40","first-page":"71","volume":"3","author":"LP Kil","year":"2013","unstructured":"Kil, L. P. et al. Bruton\u2019s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am. J. Blood Res. 3, 71\u201383 (2013).","journal-title":"Am. J. Blood Res."},{"key":"86876_CR41","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.20120332","volume":"209","author":"EM Fournier","year":"2012","unstructured":"Fournier, E. M. et al. Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice. J. Exp. Med. 209, 1797\u20131812. https:\/\/doi.org\/10.1084\/jem.20120332 (2012).","journal-title":"J. Exp. Med."},{"key":"86876_CR42","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00296-019-04445-y","volume":"39","author":"SS Ahn","year":"2019","unstructured":"Ahn, S. S. et al. Anti-smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol. Int. 39, 1937\u20131944. https:\/\/doi.org\/10.1007\/s00296-019-04445-y (2019).","journal-title":"Rheumatol. Int."},{"key":"86876_CR43","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1084\/jem.20060411","volume":"203","author":"D Savitsky","year":"2006","unstructured":"Savitsky, D. & Calame, K. B-1 B lymphocytes require Blimp-1 for immunoglobulin secretion. J. Exp. Med. 203, 2305\u20132314. https:\/\/doi.org\/10.1084\/jem.20060411 (2006).","journal-title":"J. Exp. Med."},{"key":"86876_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1084\/jem.20052204","volume":"203","author":"L Pasqualucci","year":"2006","unstructured":"Pasqualucci, L. et al. Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311\u2013317. https:\/\/doi.org\/10.1084\/jem.20052204 (2006).","journal-title":"J. Exp. Med."},{"key":"86876_CR45","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1182\/blood-2005-09-3778","volume":"107","author":"W Tam","year":"2006","unstructured":"Tam, W. et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107, 4090\u20134100. https:\/\/doi.org\/10.1182\/blood-2005-09-3778 (2006).","journal-title":"Blood"},{"key":"86876_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/leu.2016.243","volume":"31","author":"Y Xia","year":"2017","unstructured":"Xia, Y. et al. Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia 31, 625\u2013636. https:\/\/doi.org\/10.1038\/leu.2016.243 (2017).","journal-title":"Leukemia"},{"key":"86876_CR47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2326-6066.CIR-17-0582","volume":"6","author":"CH Tang","year":"2018","unstructured":"Tang, C. H. et al. Secretory IgM exacerbates Tumor Progression by inducing accumulations of MDSCs in mice. Cancer Immunol. Res. 6, 696\u2013710. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0582 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"86876_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ni.3348","volume":"17","author":"J Tellier","year":"2016","unstructured":"Tellier, J. et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat. Immunol. 17, 323\u2013330. https:\/\/doi.org\/10.1038\/ni.3348 (2016).","journal-title":"Nat. Immunol."},{"key":"86876_CR49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","volume":"100","author":"A Ferrajoli","year":"2002","unstructured":"Ferrajoli, A. et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100, 1215\u20131219 (2002).","journal-title":"Blood"},{"key":"86876_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","volume":"62","author":"H Zelova","year":"2013","unstructured":"Zelova, H. & Hosek, J. TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm. Res. 62, 641\u2013651. https:\/\/doi.org\/10.1007\/s00011-013-0633-0 (2013).","journal-title":"Inflamm. Res."},{"key":"86876_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood.2019000200","volume":"134","author":"P Davizon-Castillo","year":"2019","unstructured":"Davizon-Castillo, P. et al. TNF-alpha-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood 134, 727\u2013740. https:\/\/doi.org\/10.1182\/blood.2019000200 (2019).","journal-title":"Blood"},{"key":"86876_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41419-017-0049-9","volume":"9","author":"P Bastola","year":"2018","unstructured":"Bastola, P. & Chien, J. Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors. Cell. Death Dis. 9, 35. https:\/\/doi.org\/10.1038\/s41419-017-0049-9 (2018).","journal-title":"Cell. Death Dis."},{"key":"86876_CR53","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/icb.1997.17","volume":"75","author":"SG Tangye","year":"1997","unstructured":"Tangye, S. G. & Raison, R. L. Human cytokines suppress apoptosis of leukaemic CD5\u2009+\u2009B cells and preserve expression of bcl-2. Immunol. Cell. Biol. 75, 127\u2013135. https:\/\/doi.org\/10.1038\/icb.1997.17 (1997).","journal-title":"Immunol. Cell. Biol."},{"key":"86876_CR54","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3324\/haematol.2017.177808","volume":"103","author":"C Durr","year":"2018","unstructured":"Durr, C. et al. Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica 103, 688\u2013697. https:\/\/doi.org\/10.3324\/haematol.2017.177808 (2018).","journal-title":"Haematologica"},{"key":"86876_CR55","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends, S. et al. The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 28, 661\u2013668 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"86876_CR56","doi-asserted-by":"publisher","unstructured":"Jang, D. I. et al. The role of Tumor necrosis factor alpha (TNF-alpha) in Autoimmune Disease and current TNF-alpha inhibitors in therapeutics. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22052719 (2021).","DOI":"10.3390\/ijms22052719"},{"key":"86876_CR57","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/leu.2008.385","volume":"23","author":"JA Woyach","year":"2009","unstructured":"Woyach, J. A. et al. A phase I\/II study of Rituximab and Etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 23, 912\u2013918. https:\/\/doi.org\/10.1038\/leu.2008.385 (2009).","journal-title":"Leukemia"},{"key":"86876_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86876-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86876-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86876-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:42:15Z","timestamp":1738644135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86876-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86876"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86876-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4117"}}